Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia



Status:Recruiting
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - 70
Updated:3/1/2014
Start Date:February 2011
End Date:June 2016
Contact:Geoffrey L Uy, M.D.
Email:guy@wustl.edu
Phone:314-454-8304

Use our guide to learn which trials are right for you!

Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia

This study is designed to test the combination of Plerixafor with G-CSF for
chemosensitization in patients with relapsed or refractory AML.

In this study, we are seeking to target the leukemia microenvironment to overcome disease
resistance. We hypothesize that by disrupting the interaction of leukemic blasts with the
bone marrow microenvironment, we may sensitize leukemic blasts to the effects of cytotoxic
chemotherapy. In this study, we seek to maximize blockage of the SDF-1/CXCR4 axis through
the following:

1. Addition of G-CSF, which down regulates SDF-1 expression and acts synergistically with
plerixafor in stem cell mobilization

2. Intravenous instead of subcutaneous dosing of plerixafor to improve kinetics of
administration.

3. Dose escalation of plerixafor and twice daily dosing to maintain maximum CXCR4
blockade.

Inclusion Criteria:

1. Acute myeloid leukemia diagnosed by WHO criteria with one of the following:

- Primary refractory disease following no more than 2 cycles of induction
chemotherapy

- First relapse with no prior unsuccessful salvage chemotherapy

2. Age between 18 and 70 years old

3. ECOG performance status ≤ 3

4. Adequate organ function defined as:

- Calculated creatinine clearance ≥ 50 ml/min

- AST, ALT, total bilirubin ≤ 2 x ULN except when in the opinion of treating
physician is due to direct involvement of leukemia (eg. hepatic infiltration or
biliary obstruction due to leukemia)

- Left ventricular ejection fraction of ≥ 40% by MUGA scan or echocardiogram

5. Are surgically or biologically sterile or willing to practice acceptable birth
control, as follows:

- Females of child bearing potential must agree to abstain from sexual activity or
to use a medically approved contraceptive measure/regimen during and for 3
months after the treatment period. Women of child bearing potential must have a
negative serum or urine pregnancy test at the time of enrollment. Acceptable
methods of birth control include oral contraceptive, intrauterine device (IUD),
transdermal/implanted or injected contraceptives and abstinence.

- Males must agree to abstain from sexual activity or agree to utilize a medically
approved contraception method during and for 3 months after the treatment period

6. Able to provide signed informed consent prior to registration on study

Exclusion Criteria:

1. Acute promyelocytic leukemia (AML with t(15;17)(q22;q11) and variants)

2. Peripheral blood blast count ≥ 20 x 103 /mm3

3. Active CNS involvement with leukemia

4. Previous treatment with MEC or other regimen containing both mitoxantrone and
etoposide

5. Pregnant or nursing

6. Received any other investigational agent or cytotoxic chemotherapy (excluding
hydroxyurea) within the preceding 2 weeks

7. Received colony stimulating factors filgrastim or sargramostim within 1 week or
pegfilgrastim within 2 weeks of study

8. Severe concurrent illness that would limit compliance with study requirements
We found this trial at
4
sites
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
1 Brookings Drive
St. Louis, Missouri 63110
 (314) 935-5000
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials